• Quanterix expanded its China commercialization arrangement with Innovita as the partner secured NMPA clearances for SIMOA neurology testing.
• NMPA cleared the HD-X and SR-X instruments, enabling wider rollout of SIMOA systems in the Chinese IVD market.
• Clearances also covered four neurology biomarker kits, supporting blood-based Alzheimer’s testing and disease monitoring applications.
• Innovita plans additional China regulatory filings for more Quanterix biomarker diagnostic kits under the partnership.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202610070800BIZWIRE_USPR_____20261007_BW841334) on October 07, 2026, and is solely responsible for the information contained therein.